Wellington Management Group LLP Invests $2.99 Million in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Wellington Management Group LLP acquired a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 83,984 shares of the company’s stock, valued at approximately $2,988,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AJOVista LLC acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at about $99,000. Exchange Traded Concepts LLC lifted its stake in IDEAYA Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after acquiring an additional 1,219 shares during the last quarter. Jump Financial LLC bought a new stake in IDEAYA Biosciences in the fourth quarter worth approximately $215,000. Callan Capital LLC acquired a new position in shares of IDEAYA Biosciences during the 4th quarter worth $239,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of IDEAYA Biosciences by 405.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,453 shares of the company’s stock valued at $265,000 after purchasing an additional 5,979 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $35.11 on Monday. The firm has a fifty day moving average price of $39.00 and a two-hundred day moving average price of $40.68. IDEAYA Biosciences, Inc. has a fifty-two week low of $20.90 and a fifty-two week high of $47.74. The company has a market cap of $2.66 billion, a PE ratio of -17.47 and a beta of 0.79.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. IDEAYA Biosciences’s revenue for the quarter was down 100.0% on a year-over-year basis. Analysts expect that IDEAYA Biosciences, Inc. will post -2.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on IDYA. BTIG Research started coverage on shares of IDEAYA Biosciences in a research report on Friday, March 8th. They set a “buy” rating and a $55.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, May 8th. Citigroup upped their target price on IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. Stifel Nicolaus lifted their price target on shares of IDEAYA Biosciences from $55.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Finally, The Goldman Sachs Group decreased their price objective on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating for the company in a report on Monday, May 13th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Buy” and an average target price of $48.27.

Insider Transactions at IDEAYA Biosciences

In related news, insider Michael Anthony White sold 28,500 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total value of $1,032,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Yujiro S. Hata sold 34,433 shares of IDEAYA Biosciences stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $41.81, for a total transaction of $1,439,643.73. Following the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,342,455.47. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Anthony White sold 28,500 shares of the stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 119,644 shares of company stock valued at $4,832,228. 3.50% of the stock is owned by corporate insiders.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.